Pharmaceutical Executive-02-01-2013

Pharmaceutical Executive
Country Report

February 01, 2013

In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally: the country is dealing with patent cliffs, companies are cutting back staff, an ageing population forces the government to rethink healthcare expenditures, and big originator companies are reforming.

Pharmaceutical Executive
Features

February 01, 2013

After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. Julian Upton reports.

Pharmaceutical Executive
Column

February 01, 2013

More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.

Pharmaceutical Executive
Features

February 01, 2013

"Drug Life Optimization" can wrest more value through strategies that build a drug's brand franchise through its entire lifespan, according to Stan Bernard.

Pharmaceutical Executive
Column

February 01, 2013

After years of asking questions, the National Highway Traffic Safety Administration (NHTSA)is moving closer to a protocol "for assessing the driving-impairment risks of drugs". Ben Comer reports.

Column
Pharmaceutical Executive

February 01, 2013

Caronia decision shows the staying power of Sorrell v. IMS Health.

Pharmaceutical Executive

S

Pharmaceutical Executive
From the Editor

February 01, 2013

Today's most important public health story is the advance in our understanding of the biology of cancer, writes Pharm Exec Editor-in-Chief William Looney.

Pharmaceutical Executive
Features

February 01, 2013

Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.

Issue PDF
Pharmaceutical Executive

February 01, 2013

2013 Oncology Practice Roundtable